Understanding Australia’s influenza pandemic policy on the strategic use of the antiviral drug stockpile

James M McCaw, James G Wood, Emma S McBryde, Terry M Nolan, Joseph T Wu, Marc Lipsitch and Jodie McVernon
Med J Aust 2009; 191 (3): . || doi: 10.5694/j.1326-5377.2009.tb02720.x
Published online: 3 August 2009

Targeted post-exposure prophylaxis represents a more efficient use of the stockpile than treatment alone

With the emergence of H1N1 influenza 09 (novel human swine influenza A[H1N1] 2009), efforts to control the spread and mitigate the impact of this virus have been implemented. The Australian health management plan for pandemic influenza (2008)1 (AHMPPI) outlines a range of strategies aimed at eliminating an outbreak where possible (the “Contain” response), or reducing transmission sufficiently to allow distribution of a targeted vaccine (the “Sustain” response). Following evidence of sustained transmission within Victoria in May 2009, state and territory health departments began implementing the Contain response, with a switch to a modified Sustain response in Victoria within weeks.

  • James M McCaw1
  • James G Wood2
  • Emma S McBryde3,4
  • Terry M Nolan1
  • Joseph T Wu5
  • Marc Lipsitch6
  • Jodie McVernon1,0

  • 1 Vaccine and Immunisation Research Group, Melbourne School of Population Health, University of Melbourne and Murdoch Childrens Research Institute, Melbourne, VIC.
  • 2 School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW.
  • 3 Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC.
  • 4 Department of Medicine, University of Melbourne, Melbourne, VIC.
  • 5 Department of Community Medicine and School of Public Health, University of Hong Kong, Hong Kong.
  • 6 Department of Epidemiology and Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Mass, USA.



We thank Julie Hall (World Health Organization Regional Office for the Western Pacific), Niels Becker (National Centre for Epidemiology and Population Health, Australian National University), John Mathews, Chris McCaw and Paul Pallaghy (Melbourne School of Population Health, University of Melbourne) for discussions and comments during development of the modelling approaches that underpin this article, and members of the Scientific Influenza Advisory Group of the Chief Medical Officer of Australia for their comments. The outlined modelling studies were funded by the Australian Government Department of Health and Ageing, the National Health and Medical Research Council (NHMRC) and the United States National Institutes of Health (Models of Infectious Disease Agent Study).

Competing interests:

Marc Lipsitch has received consulting fees from the Avian/Pandemic Flu Registry, which is partly supported by Roche.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.